HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Improves On Meeting Demand, But Doesn’t Deliver Better Full-Year Forecast

Executive Summary

Lowers full-year forecast for reported sales growth to 4% to 5% from an earlier estimate of 5% to 8% despite improving to 89% on meeting demand during the April-June period from 80% during Q1.

You may also be interested in...



Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold

Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.

Church & Dwight Cuts Outlook Due To Rising Costs, Adds Suppliers To Strengthen ‘Weak Links’

“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.

Nicotine Gummies Sold For Smoking Cessation Doused Under US FDA Tobacco Regulations

FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel